CD19 and systemic lupus erythematosus: Furthermore, CABA-201 has a comparable phenotype when manufactured using a clinical manufacturing process and similar level of cytolytic activity against CD19+ Nalm6 target cells compared to FMC63 CAR T (tisanglecleucel) across a variety of E:T ratios and different donors, including an SLE donor.